Chinese Patent Medicines in Breast Cancer: Landmark 34-Year Study Maps Research Boom and Reveals a Widening Evidence Gap

Chinese patent medicines — the standardized, industrially manufactured herbal products of traditional Chinese medicine — have quietly become one of the most heavily researched complementary therapies in breast cancer care. Now, a sweeping bibliometric analysis published in Supportive Care in Cancer has mapped that research landscape across three and a half decades, and its findings are as revealing as they are unsettling. Drawing on 1,847 publications spanning 1991 to 2025, a team led by Yi Yuan and Yi Ji of Tsinghua University Yuquan Hospital and Jiangsu Province Hospital On Integration of Chinese and Western Medicine, together with colleagues at Beijing University of Chinese Medicine and other institutions, has produced the most comprehensive picture to date of how these medicines are studied, recommended, and — crucially — where the science falls short of clinical reality.

The scale of the undertaking is itself remarkable. The researchers searched five major databases simultaneously: Web of Science and PubMed for the international, English-language literature, and CNKI, WanFang, and CQVIP for the vast Chinese-language corpus that most Western observers never see. This dual-language approach matters enormously, because the overwhelming majority of research on Chinese patent medicines has been conducted in mainland China and published in Chinese journals. By preprocessing the data with Co-Occurrence 20.5 and then analyzing it with CiteSpace and R software, the team could visualize co-citation networks, keyword bursts, and institutional collaborations — essentially building a cartographic map of an entire field, with its mountains of activity, its valleys of neglect, and its emerging frontier ridges.

What the map shows is a field that has grown steadily, with annual publication output concentrated overwhelmingly in mainland China. That geographic concentration is not merely a curiosity of publishing patterns; it raises fundamental questions about the universality of the evidence base. If nearly all studies of a therapy come from one country’s healthcare system, with its particular patient populations, treatment protocols, and regulatory environment, how confidently can the findings be generalized to the diverse, multiethnic patient populations who increasingly turn to these products worldwide? The authors explicitly flag this problem, calling for more cross-regional and multiethnic studies to validate the universal applicability and safety of Chinese patent medicines before any broader use can be considered.

Perhaps the most striking finding concerns the gap between what clinical guidelines recommend and what the products’ own package inserts say. Among the top ten Chinese patent medicines with the highest volume of research, most had received recommendations from at least one clinical practice guideline — documents from bodies such as the China Anti-Cancer Association, the National Health Commission of China, and various expert consensus panels on integrated traditional Chinese and Western medicine. Yet those recommendations sometimes diverged from the package inserts, which often lacked explicit tumor indications altogether. In other words, oncologists and traditional Chinese medicine practitioners may be prescribing these medicines for cancer-related purposes that the official labeling never anticipated, let alone validated through rigorous clinical trials.

This discrepancy between actual clinical application and usage standards is the study’s central alarm bell. It is not a new problem in complementary medicine, but it is unusually acute here because Chinese patent medicines occupy a peculiar regulatory and cultural position: they are standardized pharmaceutical products, manufactured under quality controls, yet their therapeutic logic derives from a medical framework — pattern differentiation and formula composition — that does not map neatly onto modern oncology’s molecular categories. The authors argue that closing this gap requires clarifying the drugs’ mechanisms and clinical value through high-quality evidence, a process they describe as essential to the scientific and standardization development of the field.

The bibliometric analysis also exposed a fascinating linguistic and philosophical divide within the literature itself. Studies published in English-language databases tended to focus on Chinese patent medicines prepared or purified from only one or two herbal ingredients, with clearly identified primary active compounds and botanical origins. Think of β-elemene, the sesquiterpene from Curcuma species shown in laboratory studies to reverse chemoresistance in breast cancer cells by disrupting exosome-mediated resistance transmission, or astragaloside IV, the saponin from Astragalus membranaceus that enhanced paclitaxel chemosensitivity through caveolin-1-targeted oxidant damage. These are molecules a Western pharmacologist can immediately grasp: a defined compound, a defined target, a defined mechanism.

Chinese-language research, by contrast, embraces the full complexity of multi-herb formulations — the classic compound prescriptions like Xihuang Pill, a centuries-old formula whose antitumor effects in mouse models of breast cancer have been linked to reductions in regulatory T cells within the tumor microenvironment via the PI3K/AKT–AP-1 signaling pathway. This divide is more than stylistic. Single-compound agents are far easier to subject to randomized controlled trials, pharmacokinetic analysis, and regulatory scrutiny, while multi-herb formulas resist the reductionist toolkit but may capture synergistic interactions that single agents miss. The field’s future trajectory may well depend on whether these two research cultures can find a common methodological language.

Where is the intellectual energy of the field heading? The analysis identified two dominant research hotspots: the tumor microenvironment, and the strategy of reducing toxicity while enhancing efficacy in conventional antitumor therapies — the concept Chinese oncologists call ‘jian du zeng xiao.’ The first hotspot reflects mainstream cancer biology’s own migration. Chronic inflammation, immunosuppression, tumor-associated macrophages, and regulatory T cells are now recognized as central players in breast cancer progression, and traditional Chinese medicine researchers have positioned their agents as modulators of this microenvironmental ecology. The second hotspot addresses a persistent clinical pain point: chemotherapy-induced leukopenia, nausea, cancer-related fatigue, cancer pain, and cardiotoxicity drive dose reductions and treatment discontinuation, and several expert consensus documents in China now formally recommend Chinese patent medicines for managing these toxicities.

One rising star deserves particular attention: herbal polysaccharides. According to the study’s trend analysis, these complex carbohydrates — long dismissed as pharmacologically inert ‘fiber’ — are gaining both attention and academic influence within the field, appearing to be the current wave of scholarly interest. Polysaccharides from mushrooms and roots such as Astragalus have been investigated for immunomodulatory properties, and their growing bibliometric footprint suggests researchers see them as a promising interface between traditional formulations and modern immuno-oncology. Whether that promise survives contact with rigorous clinical evaluation remains to be seen, but the trend line is unmistakable.

For patients and clinicians, the study’s message is nuanced. Chinese patent medicines are widely used in cancer care, embedded in Chinese clinical guidelines, and supported by a substantial and growing research literature — 1,847 publications is not nothing. Yet the evidence architecture is uneven: recommendations sometimes outpace labeling, package inserts often lack tumor indications, the research base is geographically concentrated, and the highest-quality clinical validation remains the exception rather than the rule. The authors’ prescription is clear and measured: improve scientific rigor and standardization, clarify mechanisms and clinical value with high-quality evidence, and expand studies across regions and ethnic populations. Until then, the landscape they have mapped remains a terrain of genuine promise — and genuine uncertainty — where the gap between what is practiced and what is proven is the single most important feature on the map.

Subject of Research: Bibliometric mapping of Chinese patent medicines research in breast cancer care from 1991 to 2025

Article Title: Mapping the landscape of Chinese patent medicines in breast cancer: a multi-database bibliometric analysis (1991-2025)

Article References: Yuan, Y., Ji, Y., Wang, Z.-J., Xia, X.-P., Yang, C.-Y., Huang, R.-Y., Zhang, Y.-J., Zuo, J.-L., Liu, X.-Q., & Liu, J.-P. (2026). Mapping the landscape of Chinese patent medicines in breast cancer: a multi-database bibliometric analysis (1991-2025). Supportive Care in Cancer, 34(10), Article 967. https://doi.org/10.1007/s00520-026-11209-5

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11209-5

Keywords: breast cancer, Chinese patent medicines, traditional Chinese medicine, bibliometric analysis, complementary therapy, tumor microenvironment, chemotherapy side effects, herbal polysaccharides, clinical guidelines, evidence-based medicine, CiteSpace, supportive cancer care